Tafamadis meglumine (Vyndaqel®) for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/03/2018|
|Rapid review completed||10/05/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.|